Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results

Century Therapeutics (NASDAQ:IPSC) posted its quarterly earnings data on Wednesday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06), FiscalAI reports.

Century Therapeutics Price Performance

NASDAQ IPSC traded down $0.05 during trading on Wednesday, reaching $2.01. 336,271 shares of the company’s stock were exchanged, compared to its average volume of 1,441,638. The business has a 50 day moving average price of $2.20 and a 200-day moving average price of $2.23. The stock has a market capitalization of $362.50 million, a P/E ratio of -1.76 and a beta of 1.57. Century Therapeutics has a fifty-two week low of $0.44 and a fifty-two week high of $3.04.

Institutional Investors Weigh In On Century Therapeutics

Large investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. bought a new position in Century Therapeutics during the second quarter worth $25,000. Bank of America Corp DE lifted its stake in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after buying an additional 34,466 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics during the 2nd quarter worth about $38,000. Raymond James Financial Inc. bought a new stake in shares of Century Therapeutics during the 2nd quarter worth about $51,000. Finally, AQR Capital Management LLC grew its stake in Century Therapeutics by 358.9% in the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on IPSC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. HC Wainwright boosted their price target on Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Mizuho initiated coverage on shares of Century Therapeutics in a research note on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Century Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.